ReviewFrontiers in oncology2024
High costs, low quality of life, reduced survival, and room for improving treatment: an analysis of burden and unmet needs in glioma.
Review in Frontiers in oncology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 1 synthesis or guideline pooled it, 25 citations in OpenAlex.
- Critical regulatory roles of non-coding RNAs in driving cancer sensitivity to Carmustine: a systematic review.Naunyn-Schmiedeberg's archives of pharmacology · 2026Pooled it
- Integrated CT-PET radiogenomics and graph-based multi-task learning for preoperative prediction of key glioma molecular markers.Neuroradiology · 2026Article
- Integrating Endovascular Drug Delivery into the Therapeutic Landscape of Glioblastoma.Cancers · 2026Review
- A transformer-based multimodal deep learning model for preoperative prediction of Ki-67 expression level in glioma.BMC medical imaging · 2026Article
- Novel Experimental Therapeutic Approaches in Glioma-New Hydrazide-Hydrazones as Chemical Agents Sensitizing Glioblastoma Cell Line to Radiotherapy.International journal of molecular sciences · 2026Article
- In-hospital costs of malignant brain tumor surgery: A systematic review and quality assessment.Neuro-oncology practice · 2026Review
- SOCS3 suppresses glioblastoma growth via JAK-STAT inhibition and mitochondrial unfolded protein response activation.Cell division · 2026Article
- Socioeconomic disparities in IDH-wildtype glioblastoma survival: interactions between age and household income in a SEER cohort.Journal of neuro-oncology · 2026Article
- Machine learning-integrated network toxicology uncovers glioma targets of DEHP.Frontiers in toxicology · 2026Article
- Unveiling Anti-Cancer Potential through ADMET Prediction, Molecular Docking, Molecular Dynamics, andCurrent topics in medicinal chemistry · 2026Article
- Localized treatment of glioblastoma: a review of clinical strategies and advances in drug delivery systems.Nanomedicine (London, England) · 2025Review
- Review
- Androgen receptor inhibition sensitizes glioblastoma stem cells to temozolomide by the miR-1/miR-26a-1/miR-487b signature mediated WT1 and FOXA1 silencing.Cell death discovery · 2025Article
- Toxicological insights and safety considerations of vorasidenib in grade 2 astrocytoma and oligodendroglioma.International journal of surgery (London, England) · 2025Article
- Association between psychological resilience and symptom burden in postoperative patients with brain gliomas and its influencing factors.American journal of cancer research · 2025Article
- Identifying new therapeutics for focused ultrasound-enhanced drug delivery in the management of glioblastoma.Frontiers in oncology · 2025Review
- The role of a multidisciplinary clinic for management of patients with IDH mutant gliomas.Frontiers in oncology · 2025Article
- Challenges and Advances in Classifying Brain Tumors: An Overview of Machine, Deep Learning, and Hybrid Approaches with Future Perspectives in Medical Imaging.Current medical imaging · 2025Review
- Acid-sensing ion channel 3 is a new potential therapeutic target for the control of glioblastoma cancer stem cells growth.Scientific reports · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 4 institutions in 4 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Gliomas are a group of heterogeneous tumors that account for substantial morbidity, mortality, and costs to patients and healthcare systems globally. Survival varies considerably by grade, histology, biomarkers, and genetic alterations such as IDH mutations and
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.